2024. Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s451. DOI:https://doi.org/10.25251/skin.8.supp.451.